JPMorgan Chase chief Jamie Dimon acknowledges ‘terrible, egregious mistake’
By Lisa Rein, Sunday, May 13, 3:29 PM
JPMorgan Chase chief executive Jamie Dimon acknowledged Sunday that the bank “made a terrible, egregious mistake” by dismissing concerns about a $2 billion trading loss it disclosed last week.
“We were dead wrong” to dismiss questions about reports that a trading group in London was taking outsize positions to hedge against risk and distorting the market, Dimon told NBC’s David Gregory in an interview that aired on “Meet the Press.” The bank’s actions were “sloppy and stupid,” he said.
In a conference call with analysts in April, Dimon called the concerns a “complete tempest in a teapot.”
“There’s almost no excuse for it,” he said Sunday about the trading loss, which resulted from risky bets on credit derivatives made by the bank’s chief investment office in London.
The losses, disclosed by the bank Thursday, have reopened a long-standing clash between Capitol Hill lawmakers and Wall Street over whether banks are still taking too much risk and whether they should be pushing back against regulations passed after the financial crisis.
Although Dimon is a big Democratic donor who has had a close relationship with President Obama, the banker said Sunday that a lack of collaboration between the parties has hurt the country’s business climate.
“It’s true to say we haven’t had true, common collaboration,” he said, answering a question on whether the Obama administration has created an anti-business environment. “To me, it’s not Democrat or Republican.”
But he said, “Democrats were so tough on Republicans that you’re seeing a little bit of that give back at this point.” He urged the parties to “put their knives down and get back to work for the American public.”
Dimon said JPMorgan is open to questions from regulators on the type of trading that led to the $2 billion loss and supports giving government the authority to dismantle a failing bank, even if shareholder equity would be wiped out. He promised to get to the bottom of the mistake and learn from it.
But he has argued against strict financial regulations. He said Sunday that JPMorgan is “very strong” and acknowledged that the losses would give regulators ammunition to tighten restrictions on banks.
“This is a very unfortunate and inopportune time” for the trading losses, Dimon said, conceding that the bank “hurt ourselves and our credibility” and expects to “pay the price for that.”
Senior Democrats repeated their call for stricter regulations.
Sen. Carl M. Levin (D-Mich.) said Sunday the JPMorgan loss only confirms that banks’ pushback against new rules passed after the financial crisis will backfire.
“This was not a risk-reducing activity that they engaged in. This increased their risk,” Levin said on “Meet the Press.”
“So we’ve got to be very, very careful that the regulators here are not undermined by this huge effort to weaken the rule by putting in a huge loophole” that includes the trading that caused the JPMorgan loss, he said.
Regulators are drafting new rules governing banks. A signature feature of the changes is the Volcker Rule, a prohibition on banks engaging in speculative bets that is intended to keep them from putting federally insured deposits at risk.
The authors of the act, who include Levin, say the measure might have prevented JPMorgan’s bad trades had it been in effect.
Wall Street firms have criticized the proposed rule as broad and ill-defined and say it will force them to shed businesses and increase risks for clients.
The rule prohibits banks from speculating with their own money — rather than on behalf of their clients — but firms argue that the dividing line can be hard to define.
Dimon has said the trading involved in the $2 billion loss would not have fallen under the rule.
Rep. Barney Frank (D-Mass.), who co-wrote a regulatory law that bears his name, said on ABC’s “This Week” that he hopes the final version of the Volcker Rule will prevent the type of trading that led to the JPMorgan losses.
Posted On: 05/13/2012 4:52:42 PM
Post# of 1842
(0)
(0)
Top 10 Most Recent Blog Posts
Tilray Brands, Inc. (TLRY): A Global Cannabis Leader
Category: Stocks Total Views: 97
By : Kelly Martin Updated: 07-29-2024
Overview of Tilray Brands, Inc.
Tilray Brands, Inc. (NASDAQ: TLRY) is a pioneering company in the field of medical and recreational cannabis production and research. Headquartered in Canada, Tilray has positioned itself as a global leader with a commitment to providing safe, consistent, and reliable therapy to patients and consumers worldwide. The company operates in multiple regions, including Canada, the United States, Europe, Australia, and Latin America, serving a diverse clientele rangin... Continue Reading
Understanding the Demand Generation Process for Business Growth
Category: Business Total Views: 111
By : Ryan Hughes Updated: 07-29-2024
Introduction to Demand Generation
In the fast-paced world of digital marketing and advertising, understanding the demand generation process is crucial for business growth. Demand generation is a comprehensive strategy aimed at creating awareness and interest in a company's products or services, ultimately driving customer engagement and revenue. For advertisers, especially in the realm of connected TV advertising, mastering demand generation can significantly enhance performance marketing... Continue Reading
Philips Unveils New AI Cardiovascular Ultrasound Platform
Category: Stocks Total Views: 106
By : Henry Turner Updated: 07-29-2024
Philips Reports Strong Order Intake Growth in Q2 2024
With a 9% rise over past periods, Philips's order intake in Q2 2024 rose significantly. Mostly, the North American market drove this expansion. With group sales of EUR 4.5 billion, the company said that comparable sales had risen by 2%. Operations brought in EUR 816 million, of which EUR 538 million came from insurance earnings. The changed EBITA margin climbed to 11.1% of sales. Apart from a free cash outflow of EUR 64 million, Philip... Continue Reading
High-Purity Canola Protein: Burcon’s New Achievement
Category: Stocks Total Views: 146
By : Dominic Sanders Updated: 07-29-2024
Burcon NutraScience Achieves Milestone in Canola Protein Production
Leader in plant-based protein technologies, Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) has effectively finished its first end-to-end validation trial for manufacturing high-purity canola protein isolate. For Burcon's goal of releasing creative, plant-based protein solutions onto the market, this success represents a major forward step.
Commercialization of Canola Protein Technology
Burcon's commerc... Continue Reading
Cosa's Orbit Project Gains Untapped Exploration Areas
Category: Stocks Total Views: 150
By : Caleb Price Updated: 07-29-2024
Acquisition of Mineral Claims in Athabasca Basin
Skyharbour Resources LTD. has signed an asset purchase agreement with Cosa Resources Corp. Signed July 26, 2024, the agreement calls for acquiring two mineral claims in the Athabasca Basin, Saskatchewan. With 12,718 hectares, these claims will double the footprint of the Orbit uranium project. With this purchase, Cosa will be able to increase its eight kilometer control of untested strike length. The claims follow trend with uranium mineralizat... Continue Reading
Hyperfast Title Joins reAlpha's AI Homebuying Platform
Category: Stocks Total Views: 176
By : Riley Hayes Updated: 07-29-2024
reAlpha Acquires 85% Stake in Hyperfast Title, LLC
85% of Hyperfast Title, LLC. has been acquired by reAlpha Tech Corp. Hyperfast calls Florida, Virginia, and Tennessee home. This purchase expands the portfolio of reAlpha with title and settlement services. Re Alpha is renowned for creating real estate artificial intelligence technologies. The purchase from Madison Settlement Services fits the expansion plan of reAlpha. This action enhances the homebuying market offerings from reAlpha. The in... Continue Reading
Long-term Projections for AI Technologies Development
Category: Business Total Views: 148
By : Hannah Lewis Updated: 07-29-2024
The Rise of Generative AI: Transforming Industries and Investment Strategies
By allowing the creation of fresh content—text and images as well as music and design—generative artificial intelligence is changing sectors. Companies use this technology to improve operations and boost inventiveness. Generative artificial intelligence creates tailored marketing materials in advertising, so boosting interaction. In the medical field, it helps with new medical imaging creation and drug di... Continue Reading
New Alzheimer's Treatment: Anavex's Blarcamesine Success
Category: Stocks Total Views: 209
By : Addison Perry Updated: 07-29-2024
Anavex Life Sciences Reports Promising Results for Alzheimer's Treatment
From its Phase IIb/III study on blarcamesine (ANAVEX®2-73), a medication for early Alzheimer's disease (AD), Anavex Life Sciences Corp. (Nasdaq: AVXL) has reported encouraging findings. Leading neurology specialist Dr. Marwan Noel Sabbagh delivered the data at the 2024 Alzheimer's Association International Conference (AAIC). Taken once daily, blarcamesine has shown great promise in halting the advance of ... Continue Reading
Windtree's Latest Advances: Istaroxime Clinical Trials
Category: Stocks Total Views: 273
By : Lucas Young Updated: 07-28-2024
Windtree Therapeutics Updates Istaroxime Clinical Development and Trial Data
Providing a thorough update on the clinical and business development of istaroxime, Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company committed to developing creative therapies for critical diseases, has This first-in-class treatment seeks to raise blood pressure, preserve or increase renal function, and strengthen systolic contraction and diastolic relaxation of the heart. In three Phase 2 trials... Continue Reading
SEC Charges Citron Capital in Multi-Year Fraud Scheme
Category: Investing Total Views: 257
By : Evelyn Baker Updated: 07-28-2024
SEC Charges Andrew Left and Citron Capital in $20 Million Fraud Scheme
Andrew Left and his company, Citron Capital LLC, have been charged with a $20 million fraud by the Securities and Exchange Commission (SEC). They are activists short sellers. The SEC complaint claims Left recommended stock positions using his Citron Research website and social media platform. He said these positions complemented Citron Capital's and his own investments. Left's recommendations, according to the SEC,... Continue Reading